There are no known specific ligands for alpha-synuclein PET imaging. Molecular docking studies were carried out with beta-Amyloid and tau proteins. We found ten molecules that sowed higher affinity towards alpha-synuclein over beta-Amyloid and tau.
Our goal is to find a alpha-synuclein lead PET ligand by in vitro and in vivo studies. These will be placed in clinical studies for Parkinson's disease early stage diagnosis by PET imaging.